SCHEDULE: PAVmed Boosts Lucid Diagnostics Stake to 28.3%
Beneficial Ownership Amendment
PAVmed Inc. has increased its beneficial ownership in Lucid Diagnostics Inc. to 28.3%, solidifying its influence through new stock awards and voting agreements.
Summary
- PAVmed Inc. (the "Reporting Person") has filed an Amendment No. 5 to its Schedule 13D, reporting beneficial ownership of 38,816,903 shares of Lucid Diagnostics Inc. ("Issuer") Common Stock, representing 28.3% of the class.
- The Reporting Person, as the parent company, holds significant influence over the Issuer, with the power to significantly influence the election of directors and other matters requiring shareholder votes.
- On February 20, 2025, the Issuer granted restricted stock awards to its officers (Dr. Aklog, Mr. McGrath, Mr. O'Neil, Mr. Gordon) covering 300,000 shares each, and to directors (Mr. Sparks, Ms. White) covering 112,800 shares each, all vesting on May 30, 2028.
- On September 25, 2025, a trust controlled by Mr. Glennon, a Principal of PAVmed, purchased 129,000 shares of Common Stock in open market transactions at approximately $1.04 per share, totaling $133,782.70.
- PAVmed entered into a new Voting Agreement on October 9, 2025, with a stockholder, granting a proxy over 3,177,500 common stock votes and 3,862,911 other capital stock votes.
- Previous voting agreements with certain officers of the Issuer cover 4,336,959 common stock votes.
- Certain Principals of PAVmed, who also serve as officers and directors of Lucid Diagnostics, entered into 45-day lockup agreements on September 10, 2025, in connection with an underwritten offering of Common Stock by the Issuer.
Sentiment
Score: 6
Explanation: The filing indicates a strengthening of control and commitment from the parent company, PAVmed, through increased beneficial ownership, new voting agreements, and insider stock awards/purchases. While not a performance report, these actions generally signal confidence. However, the potential for future share transactions by the reporting person and principals introduces some uncertainty, preventing a higher score.
Positives
- Increased beneficial ownership by PAVmed Inc. to 28.3% demonstrates a strong commitment and strategic interest in Lucid Diagnostics Inc.
- Restricted stock awards granted to officers and directors of Lucid Diagnostics Inc. align management and board interests with long-term company performance.
- Open market purchase of 129,000 shares by a trust controlled by a PAVmed Principal indicates insider confidence in the Issuer's valuation.
Risks
- PAVmed Inc. and its Principals may acquire additional securities or sell existing holdings in the open market or privately negotiated transactions, which could impact share price and ownership structure.
- The significant influence of PAVmed Inc. as the parent company, holding 28.3% of voting power, could lead to decisions primarily benefiting the parent rather than all shareholders.
- The issuance of restricted stock awards, while aligning interests, represents potential future dilution for existing shareholders upon vesting.
Future Outlook
PAVmed Inc. intends to continuously review its ownership of Lucid Diagnostics Inc. and may acquire additional securities or sell existing holdings based on an evaluation of the Issuer's business, financial condition, operations, prospects, market conditions, and alternative investment opportunities.
Industry Context
PAVmed Inc. operates as a diversified commercial-stage medical technology company, with Lucid Diagnostics Inc. as its subsidiary focused on diagnostics. This filing underscores the strategic control and integration between a parent medical technology firm and its diagnostics-focused subsidiary, a common structure in the healthcare industry to leverage specialized expertise while maintaining overarching corporate direction.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Voting Control | PAVmed Inc. entered into a new Voting Agreement on October 9, 2025, with a stockholder, granting it a proxy over 3,177,500 common stock votes and 3,862,911 other capital stock votes, further consolidating its voting power. | October 9, 2025 | Increases PAVmed's ability to influence shareholder decisions, including director elections and other corporate matters, potentially strengthening its control over Lucid Diagnostics Inc. |
| Interlocked Management/Board | Several executive officers and directors of PAVmed Inc. (Dr. Aklog, Mr. McGrath, Mr. O'Neil, Mr. Gordon, Mr. Sparks, Ms. White) also serve as officers and/or directors of Lucid Diagnostics Inc. | Ongoing | Ensures close strategic alignment and operational oversight between the parent and subsidiary, but also raises potential for conflicts of interest in decisions affecting both entities. |
| Related Party Agreements | PAVmed Inc. is party to a Management Services Agreement (MSA) and a Payroll and Benefit Expense Reimbursement Agreement (PBERA) with Lucid Diagnostics Inc., which contain obligations related to the acquisition, transfer, or voting of Common Stock. | MSA: May 12, 2018 (last amended May 12, 2025); PBERA: November 30, 2022 | Formalizes the operational and financial relationship between the parent and subsidiary, potentially influencing resource allocation and strategic direction. |
Related Party Transactions
- Restricted stock awards granted by Lucid Diagnostics Inc. to officers and directors who are also Principals of PAVmed Inc. (Dr. Aklog, Mr. McGrath, Mr. O'Neil, Mr. Gordon, Mr. Sparks, Ms. White).
- Open market purchase of 129,000 shares of Common Stock by a trust controlled by Mr. Glennon, a Principal of PAVmed Inc.
- Voting Agreements between PAVmed Inc. and certain officers/stockholders of Lucid Diagnostics Inc.
- Management Services Agreement (MSA) and Payroll and Benefit Expense Reimbursement Agreement (PBERA) between PAVmed Inc. and Lucid Diagnostics Inc.
Stakeholder Impact
- Shareholders: PAVmed's increased control and potential future transactions could influence share price and voting power. Restricted stock awards may lead to future dilution.
- Employees: Officers and directors of Lucid Diagnostics Inc. received restricted stock awards, aligning their incentives with company performance.
- Creditors: The Debt Exchange Agreement and Security and Pledge Agreement with a note holder indicate ongoing financial arrangements that could impact the company's capital structure.
Next Steps
- PAVmed Inc. will continue to review its ownership of Lucid Diagnostics Inc. on an ongoing basis.
- PAVmed Inc. and its Principals may acquire additional securities or sell existing holdings of Lucid Diagnostics Inc. in the future, dependent on various market and company-specific factors.
- Restricted stock awards granted to officers and directors are subject to vesting on May 30, 2028.
Key Dates
| Date | Description |
|---|---|
| May 12, 2018 | Initial date of the Management Services Agreement (MSA) between PAVmed and Lucid Diagnostics. |
| April 4, 2022 | Date of the Security and Pledge Agreement between PAVmed and a holder of its convertible notes. |
| November 30, 2022 | Date of the Payroll and Benefit Expense Reimbursement Agreement (PBERA) between PAVmed and Lucid Diagnostics. |
| November 12, 2024 | Date of the Issuer Note Securities Purchase Agreement, which included voting obligations for PAVmed. |
| November 15, 2024 | Date of the Debt Exchange Agreement between PAVmed and a holder of its convertible notes. |
| December 12, 2024 | Date of Amendment No. 4 to the Schedule 13D filing. |
| February 20, 2025 | Lucid Diagnostics Inc. granted restricted stock awards to its officers and directors. |
| March 24, 2025 | Date of Lucid Diagnostics Inc.'s Annual Report on Form 10-K, describing the MSA and PBERA. |
| May 12, 2025 | Most recent amendment date for the Management Services Agreement (MSA). |
| September 10, 2025 | Date of an underwritten offering of Common Stock by Lucid Diagnostics Inc., leading to lockup agreements for certain Principals. |
| September 25, 2025 | A trust controlled by Mr. Glennon purchased 129,000 shares of Common Stock in open market transactions. |
| October 9, 2025 | Date of a new Voting Agreement between PAVmed Inc. and a stockholder of Lucid Diagnostics Inc. |
| October 10, 2025 | Filing date of this Amendment No. 5 to Schedule 13D. |
| May 30, 2028 | Vesting date for restricted stock awards granted to Lucid Diagnostics Inc. officers and directors on February 20, 2025. |
Recommendation
holdPAVmed Inc. has solidified its control over Lucid Diagnostics Inc. by increasing its beneficial ownership to 28.3% and securing additional voting proxies. While this indicates strong commitment from the parent company and insiders, the filing primarily details ownership structure and related agreements rather than operational performance or new strategic initiatives that would warrant a stronger buy or sell recommendation. The mention of a recent underwritten offering and potential future share transactions by the reporting person and principals introduces some uncertainty, suggesting a 'hold' position until further operational or financial updates are available.
Keywords
Lucid Diagnostics, PAVmed, Schedule 13D, Beneficial Ownership, Restricted Stock, Voting Agreement, Medical Technology, Diagnostics, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.